Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Analytical validity of a microRNA-based assay for diagnosing indeterminate thyroid FNA smears from routinely prepared cytology slides

H. Benjamin, T. Schnitzer-Perlman, A. Shtabsky, CJ. VandenBussche, SZ. Ali, Z. Kolar, F. Pagni, . , D. Bar, E. Meiri,

. 2016 ; 124 (10) : 711-721. [pub] 20160525

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013828

BACKGROUND: The majority of thyroid nodules are diagnosed using fine-needle aspiration (FNA) biopsies. The authors recently described the clinical validation of a molecular microRNA-based assay, RosettaGX Reveal, which can diagnose thyroid nodules as benign or suspicious using a single stained FNA smear. This paper describes the analytical validation of the assay. METHODS: More than 800 FNA slides were tested, including slides stained with Romanowsky-type and Papanicolaou stains. The assay was examined for the following features: intranodule concordance, effect of stain type, minimal acceptable RNA amounts, performance on low numbers of thyroid cells, effect of time since sampling, and analytical sensitivity, specificity, and reproducibility. RESULTS: The assay can be run on FNA slides for which as little as 1% of the cells are thyroid epithelial cells or from which only 5 ng of RNA have been extracted. Samples composed entirely of blood failed quality control and were not classified. Stain type did not affect performance. All slides were stored at room temperature. However, the length of time between FNA sampling and processing did not affect assay performance. There was a high level of concordance between laboratories (96%), and the concordance for slides created from the same FNA pass was 93%. CONCLUSIONS: The microRNA-based assay was robust to various physical processing conditions and to differing sample characteristics. Given the assay's performance, robustness, and use of routinely prepared FNA slides, it has the potential to provide valuable aid for physicians in the diagnosis of thyroid nodules. Cancer Cytopathol 2016;124:711-21. © 2016 Rosetta Genomics. Cancer Cytopathology published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013828
003      
CZ-PrNML
005      
20170425101440.0
007      
ta
008      
170413s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cncy.21731 $2 doi
035    __
$a (PubMed)27223344
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Benjamin, Hila $u Rosetta Genomics, Inc, Philadelphia, Pennsylvania.
245    10
$a Analytical validity of a microRNA-based assay for diagnosing indeterminate thyroid FNA smears from routinely prepared cytology slides / $c H. Benjamin, T. Schnitzer-Perlman, A. Shtabsky, CJ. VandenBussche, SZ. Ali, Z. Kolar, F. Pagni, . , D. Bar, E. Meiri,
520    9_
$a BACKGROUND: The majority of thyroid nodules are diagnosed using fine-needle aspiration (FNA) biopsies. The authors recently described the clinical validation of a molecular microRNA-based assay, RosettaGX Reveal, which can diagnose thyroid nodules as benign or suspicious using a single stained FNA smear. This paper describes the analytical validation of the assay. METHODS: More than 800 FNA slides were tested, including slides stained with Romanowsky-type and Papanicolaou stains. The assay was examined for the following features: intranodule concordance, effect of stain type, minimal acceptable RNA amounts, performance on low numbers of thyroid cells, effect of time since sampling, and analytical sensitivity, specificity, and reproducibility. RESULTS: The assay can be run on FNA slides for which as little as 1% of the cells are thyroid epithelial cells or from which only 5 ng of RNA have been extracted. Samples composed entirely of blood failed quality control and were not classified. Stain type did not affect performance. All slides were stored at room temperature. However, the length of time between FNA sampling and processing did not affect assay performance. There was a high level of concordance between laboratories (96%), and the concordance for slides created from the same FNA pass was 93%. CONCLUSIONS: The microRNA-based assay was robust to various physical processing conditions and to differing sample characteristics. Given the assay's performance, robustness, and use of routinely prepared FNA slides, it has the potential to provide valuable aid for physicians in the diagnosis of thyroid nodules. Cancer Cytopathol 2016;124:711-21. © 2016 Rosetta Genomics. Cancer Cytopathology published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a tenkojehlová biopsie $7 D044963
650    _2
$a folikulární papilární karcinom $x diagnóza $x genetika $7 D018265
650    _2
$a cytodiagnostika $x metody $7 D003581
650    _2
$a lidé $7 D006801
650    _2
$a mikro RNA $x genetika $7 D035683
650    _2
$a diagnostické techniky molekulární $x metody $x normy $7 D025202
650    _2
$a prognóza $7 D011379
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a odběr biologického vzorku $x metody $7 D013048
650    _2
$a nádory štítné žlázy $x diagnóza $x genetika $7 D013964
650    _2
$a uzly štítné žlázy $x diagnóza $x genetika $7 D016606
650    _2
$a validační studie jako téma $7 D054928
655    _2
$a časopisecké články $7 D016428
700    1_
$a Schnitzer-Perlman, Temima $u Rosetta Genomics Ltd, Rehovot, Israel.
700    1_
$a Shtabsky, Alexander $u Pathology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a VandenBussche, Christopher J $u The Johns Hopkins University School of Medicine, Baltimore, Maryland.
700    1_
$a Ali, Syed Z $u The Johns Hopkins University School of Medicine, Baltimore, Maryland. $7 gn_A_00004195
700    1_
$a Kolar, Zdenek $u Institute of Clinical and Molecular Pathology and Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital of Olomouc, Olomouc, Czech Republic.
700    1_
$a Pagni, Fabio $u Department of Surgery and Translational Medicine, Pathology, University of Milano-Bicocca, Monza, Italy.
700    1_
$a , $u Rosetta Genomics, Inc, Philadelphia, Pennsylvania. Rosetta Genomics Ltd, Rehovot, Israel.
700    1_
$a Bar, Dganit $u Rosetta Genomics Ltd, Rehovot, Israel.
700    1_
$a Meiri, Eti $u Rosetta Genomics Ltd, Rehovot, Israel. meirie@rosettagx.com.
773    0_
$w MED00001036 $t Cancer cytopathology $x 1934-6638 $g Roč. 124, č. 10 (2016), s. 711-721
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27223344 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170425101757 $b ABA008
999    __
$a ok $b bmc $g 1200293 $s 974606
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 124 $c 10 $d 711-721 $e 20160525 $i 1934-6638 $m Cancer cytopathology $n Cancer Cytopathol $x MED00001036
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace